As­traZeneca’s PARP drug Lyn­parza eas­i­ly outscores chemo in PhI­II breast can­cer study

As­traZeneca ap­pears ready to start broad­en­ing the mar­ket for its PARP in­hibitor Lyn­parza. AS­CO or­ga­niz­ers picked the phar­ma gi­ant’s Phase III da­ta for HER-2 neg­a­tive metasta­t­ic breast can­cer for the Sun­day spot­light. And it’s not hard to see why.

The drug was linked with tu­mor shrink­age in 60% of the pa­tients with germline BR­CA1 or BR­CA2 mu­ta­tions tak­ing the drug, com­pared to 29% in the chemo group.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.